ES2582041T3 - Anticuerpo que se une específicamente a la microvasculatura sinovial de pacientes con artritis - Google Patents

Anticuerpo que se une específicamente a la microvasculatura sinovial de pacientes con artritis Download PDF

Info

Publication number
ES2582041T3
ES2582041T3 ES11764844.4T ES11764844T ES2582041T3 ES 2582041 T3 ES2582041 T3 ES 2582041T3 ES 11764844 T ES11764844 T ES 11764844T ES 2582041 T3 ES2582041 T3 ES 2582041T3
Authority
ES
Spain
Prior art keywords
seq
arthritis
patients
antibody
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11764844.4T
Other languages
English (en)
Spanish (es)
Inventor
Costantino Pitzalis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary and Westfiled College University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary and Westfiled College University of London filed Critical Queen Mary and Westfiled College University of London
Application granted granted Critical
Publication of ES2582041T3 publication Critical patent/ES2582041T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
ES11764844.4T 2010-09-30 2011-09-30 Anticuerpo que se une específicamente a la microvasculatura sinovial de pacientes con artritis Active ES2582041T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201016494 2010-09-30
GBGB1016494.5A GB201016494D0 (en) 2010-09-30 2010-09-30 Polypeptide
PCT/GB2011/051854 WO2012042270A1 (en) 2010-09-30 2011-09-30 Antibody specifically binding synovial microvasculature of arthritis patients

Publications (1)

Publication Number Publication Date
ES2582041T3 true ES2582041T3 (es) 2016-09-08

Family

ID=43243319

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11764844.4T Active ES2582041T3 (es) 2010-09-30 2011-09-30 Anticuerpo que se une específicamente a la microvasculatura sinovial de pacientes con artritis

Country Status (8)

Country Link
US (1) US9416174B2 (enExample)
EP (1) EP2621948B1 (enExample)
JP (1) JP6134266B2 (enExample)
CN (1) CN103403028B (enExample)
CA (1) CA2849982A1 (enExample)
ES (1) ES2582041T3 (enExample)
GB (1) GB201016494D0 (enExample)
WO (1) WO2012042270A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968556A1 (en) * 2013-03-13 2016-01-20 University Of Kentucky Research Foundation Methods of administering igg1 antibodies and methods of suppressing angiogenesis
GB201315788D0 (en) * 2013-09-05 2013-10-23 Univ London Queen Mary Molecule
EP3099712A4 (en) 2014-01-31 2017-11-08 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43
US10092891B2 (en) * 2014-04-25 2018-10-09 University Of Florida Research Foundation, Incorporated Controlling the activity of growth factors, particularly TGF-β, in vivo
GB201418626D0 (en) 2014-10-20 2014-12-03 Univ London Queen Mary Method
CN110957031B (zh) * 2019-12-13 2023-09-22 重庆首厚智能科技研究院有限公司 一种疾病预防信息服务平台
CN119125571A (zh) * 2024-08-19 2024-12-13 安徽医科大学 用于类风湿关节炎诊断的生物标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
WO2005058352A2 (en) 2003-12-17 2005-06-30 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
CA2575791A1 (en) * 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US20090098536A1 (en) * 2007-10-12 2009-04-16 C-A-I-R- Biosciences Gmbh Method for subgroup analysis in subjects having or being suspected of having inflammatory disease, use of anti-p38MAPK antibodies, kits and their use
BRPI0819063A2 (pt) * 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica

Also Published As

Publication number Publication date
EP2621948A1 (en) 2013-08-07
US9416174B2 (en) 2016-08-16
JP6134266B2 (ja) 2017-05-24
JP2014501490A (ja) 2014-01-23
EP2621948B1 (en) 2016-04-13
CA2849982A1 (en) 2012-04-05
WO2012042270A1 (en) 2012-04-05
GB201016494D0 (en) 2010-11-17
US20130266587A1 (en) 2013-10-10
CN103403028B (zh) 2016-08-24
HK1189004A1 (zh) 2014-05-23
CN103403028A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
ES2542757T3 (es) Anticuerpos humanizados específicos de la forma protofibrilar del péptido beta-amiloide
AR126555A2 (es) Anticuerpos de oncostatina m humana y métodos de uso
RU2018133708A (ru) Антитела, обладающие специфичностью к btla, и их использование
ES2689080T3 (es) Anticuerpos que se unen a TL1A y sus usos
AR082916A1 (es) Moleculas de union a 4-1bb
HRP20240774T1 (hr) Anti-il-33 antitijela i njihove upotrebe
JP2016531546A5 (enExample)
AR108449A1 (es) Composición farmacéutica
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20251579A1 (es) Anticuerpos especificos para cd70 y sus usos
PE20141162A1 (es) Anticuerpos anti-il-23
RU2015100656A (ru) Способ получения конъюгатов fc-фрагмента антитела, включающих по меньшей мере одну связывающую группировку, которая специфически связывается с мишенью, и их применения
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
BRPI0610796B8 (pt) anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo
HRP20190714T1 (hr) Neutralizirajuća protutijela anti-influenca a virusa i njihova uporaba
AR110755A1 (es) Anticuerpos dirigidos a hueso
RU2011103199A (ru) Антитела против cdh3, меченные радиоизотопной меткой, и их применение
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
HRP20201377T1 (hr) Vezujuće molekule specifične za il-21 i njihova upotreba
ES2566737T3 (es) Métodos de modificación de anticuerpos y anticuerpos modificados con propiedades funcionales mejoradas
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
RU2020113713A (ru) Слитый белок, содержащий молекулу fgf-18
MX2018013176A (es) Anticuerpos anti-basigin humanizados y el uso de los mismos.
RU2015126663A (ru) Гуманизированное антитело против hmgb1 или антиген-связывающий фрагмент указанного антитела
RU2017122172A (ru) Антитела к IL-17C